This dynamic presentation is from our July 2020 edition of Psychedelic Capital. You can get FREE access to recordings here using discount code ‘PSYCAP’! To learn more about our amazing Psychedelic Capital sponsors, click here!

The modern psychedelic renaissance has spurred the revival of groundbreaking clinical research into these novel compounds. As the movement to medicalize psychedelic drugs advances, one company ready to make a significant impact is FIVE Pharmaceuticals. The FIVE brand represents their focus on the five key controlled substances Ketamine, Psilocybin, MDMA, DMT & Mescaline under their 5 corporate branches: sciences, pharmaceuticals, labs, research and clinical trials. Here are three key takeaways from their insightful presentation at our July Psychedelic Capital event.

Five pharmaceuticals ketamine MDMA Psilocybin DMT Mescaline clinical trial

Key Takeaway #1: FIVE is at the Forefront of Psychedelic Pharmaceuticals  

Compounds like psilocybin and MDMA are rapidly progressing through the regulatory pipeline of drug development and testing. The team at FIVE Pharma is at the forefront of this emerging pharmaceutical psilocybin and controlled substances market with a go-public path set to launch in the fall of 2020. They plan to utilize their novel drugs to help patients with a variety of challenging mental health conditions, including PTSD, treatment-resistant depression, and addiction. From R&D and clinical trials to commercial re-sale, the FIVE team is poised to take on multiple facets of the emerging psychedelic medicine industry. 

Their pathway to revenue entails a detailed 4-step process:

  1. Licensing – applications for Section 56.1 exemptions and Section 9 for R&D, clinical trials and commercial re-sale with Health Canada.
  2. Clinical Trials – collection of data and medical analyses of Veterans and first responders suffering from PTSD and depression.
  3. Extraction & Formulation – organic and synthetic production of Psilocybin products and IP formulations for re-sale and internal use.
  4. Medical Psilocybin – FIVE working with MD’s and wellness clinics to supply Canadians with medical grade IP formulated products approved by Health Canada and GMP standards 
Five pharmaceuticals ketamine MDMA Psilocybin DMT Mescaline clinical trial

Key Takeaway #2: FIVE is Directly Helping Veterans & First Responders

There has been a significant push by major players in the psychedelic space to provide psychedelic therapy to veterans and first responders, a demographic in which conditions like PTSD are particularly prevalent. Currently, about 10% of Canadian veterans currently develop PTSD–and the numbers for treatment-resistant depression and chronic pain are even more bleak. The need for offering better mental healthcare to this demographic is greater now than ever before. 

In an effort to meet this gap, providing high-quality psychedelic therapies to Canadian veterans is a major focus of the FIVE Pharmaceuticals team. They plan to accomplish this through Health Canada licensing, Good Manufacturing Practices and ISO 9001 standards. With experience in the medical cannabis and Veterans advocacy space, FIVE advisor Arron Victory shares deep insights about his efforts towards helping Veterans receive better mental healthcare in his intriguing PsyCap talk. These compounds have enormous potential in healing this important demographic and this is certainly an area the FIVE team intends to excel in.

Want to learn more about how psychedelic therapy in veterans and first responders is poised to help psychedelics garner bipartisan political support ahead of the 2020 elections? Check out this Microdose original blog: “3 Reasons Psychedelic Medicine Is Projected to Win Bipartisan Political Support Ahead of 2020 Elections”

Key Takeaway #3: FIVE’s Dynamic Leadership Team is Built for Success

If there’s one thing the drug development space requires, it’s experienced and dynamic leadership. The team at FIVE Pharmaceuticals consists of seasoned entrepreneurs clinicians and scientists with impressive backgrounds. Each member of the management team has a unique skill set that, once assembled, creates a trailblazing pharmaceutical company aiming to be one of the first Canadian public companies to execute clinical trials in the psilocybin sector. For instance, their chief science officer, Dr. Orion Lekos, has conducted clinical trials on a global scale and has been working with medicinal plants and mushrooms for twenty years! Their enterprising CEO, Tyler Powell, has fifteen years of entrepreneur and finance experience with over 10 companies taken public on Candian, US and German exchanges. He has raised tens of millions in corporate financings through different channels along the way. From their skilled executives to their experienced and talented advisors, FIVE has built a powerful leadership team to take on psychedelic drug research and development. Their talk at psychedelic capital was certainly notable and one you won’t want to miss.

Five pharmaceuticals ketamine MDMA Psilocybin DMT Mescaline clinical trial

A Look Ahead for FIVE Pharmaceuticals

Between their veteran focused research, groundbreaking clinical trials and dynamic leadership team, the team at FIVE is positioned to make a massive impact on the emerging psychedelic landscape. Navigating the unexplored waters of psychedelic therapy will demand innovative and experienced leadership. The team at FIVE is equipped for success and is certainly a company to watch out for as the psychedelic renaissance continues to unravel. 

You can get FREE access to recordings here using discount code ‘PSYCAP’!

Five pharmaceuticals ketamine MDMA Psilocybin DMT Mescaline clinical trial